SEQUENOM and Icelandic Genomics New Research Collaboration
SAN DIEGO, and REYKJAVIK, Iceland, Feb. 9 — SEQUENOM, Inc. (Nasdaq: SQNM) and Iceland Genomics Corporation (Iceland Genomics), a privately-held company, entered into a research collaboration to analyze SEQUENOM’s proprietary panels of genetic markers associated with breast and prostate cancer in Icelandic patient samples. The results of this collaboration could provide further validation of SEQUENOM’s genetic markers predisposing for breast and prostate cancer, and improve the understanding of the role of these genetic markers in disease onset, progression and therapeutic response.
Read the full press release here.
News Source: SEQUENOM
15 June 2022
Startup Call Invites New Businesses to Turku